Clinical Performance Of Next-Generation Bioactive Materials In Maxillofacial Hard Tissue Reconstruction
Maxillofacial reconstruction, bioactive materials, tissue engineering, 3Dprinted scaffolds, bone regeneration, biomaterials.
AuthorsABSTRACTMaxillofacial hard tissue defects present significant clinical challenges due to the structural, functional, and aesthetic demands of the craniofacial region. Traditional grafting approaches, while effective, remain limited by donor site morbidity, restricted availability, and variable regenerative outcomes, prompting the exploration of next-generation bioactive materials. This comprehensive review synthesizes current evidence on smart biomaterials, calcium phosphate systems, bioactive glass formulations, hydrogels, and advanced composite scaffolds used in maxillofacial reconstruction. A narrative methodology was employed, drawing from major scientific databases to evaluate studies focused on material design, biological performance, scaffold architecture, and translational potential. Findings indicate that smart and bioactive materials exhibit strong osteogenic and angiogenic capabilities, while 3D-printed scaffolds offer improved structural precision, controlled porosity, and enhanced mechanical stability. Polymer-reinforced constructs, modified cements, and hydrogel-based systems demonstrate significant benefits in cellular integration, vascularization, and defect-specific regeneration. Multifunctional composite scaffolds incorporating drug delivery or tumourinhibiting capabilities further expand clinical possibilities, particularly in oncologic reconstruction. Despite these advances, challenges remain regarding long-term stability, degradation control, and large-scale clinical validation. The next-generation bioactive materials and engineered scaffolds show strong promise in improving outcomes in maxillofacial hard tissue reconstruction. Continued innovation and interdisciplinary research will be essential for optimizing material performance and advancing their clinical adoption.
INTRODUCTIONMaxillofacial hard tissue defects arising from trauma, congenital anomalies, tumour resections, infections, or degenerative conditions remain a significant clinical challenge due to the functional and aesthetic complexities of the craniofacial region. Traditional reconstruction has long relied on autologous bone grafts, which remain the gold standard because of their inherent osteogenic, osteoconductive, and osteoinductive properties. However, issues such as donor site morbidity, graft resorption, limited availability, and extended operative times have encouraged the exploration of alternative materials for bone regeneration. With advances in materials science and tissue engineering, biomaterial scaffolds have become central to overcoming the limitations of traditional grafting approaches, offering enhanced biological functionality, controlled degradation, and customized structural properties suitable for maxillofacial reconstruction.1 These developments have created new therapeutic pathways that aim not merely to replace missing tissue but to actively stimulate bone regeneration within the defect site. In recent decades, guided bone regeneration (GBR) has evolved into a fundamental technique for managing craniofacial and alveolar bone deficiencies. Earlier GBR materials consisted mainly of passive barrier membranes; however, modern versions integrate biofunctional properties,
••••••••••••••••••••••••••••••••
ejprd.org - Published by Dennis Barber Journals. Barber Ltd. All rights reserved
EJPRD
Copyright ©2025 by Dennis